John V. Oyler.

John V.

Oyler co-founded and runs BeOne Medicines (formerly BeiGene), the global oncology biotechnology company that has become one of the most consequential cancer drug developers of the past decade. BeOne's lead product, the BTK inhibitor Brukinsa, has achieved leadership position in several hematologic cancer indications and demonstrated superior efficacy in head-to-head trials against the prior standard of care - an unusually clear scientific win in oncology. Oyler was named the 2025 EY Entrepreneur of the Year National Health Award winner. Under his leadership, the company has built one of the largest clinical-stage oncology pipelines in the industry and expanded into dozens of countries across Europe, North America, and Asia. Before BeOne, he co-founded and led several other biotechnology companies including BioDuro. Building a genuinely global, scientifically rigorous oncology company that competes at the highest levels of clinical science against the largest multinational pharmaceutical companies is rare - most biotechs either remain regional or get acquired before achieving it. BeOne's trajectory puts Oyler in a very small group who have actually done it.